Clinical Trial

Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration

Study acronym: GA-PRP
Completed
View on ClinicalTrials.gov →
Summary
This study investigates the effects of subtenon autologous platelet-rich plasma (PRP) injections on retinal structure and visual function in patients with advanced dry age-related macular degeneration (AMD). PRP is derived from the patient's own blood and contains growth factors that may support cell survival and tissue repair. These factors are thought to help reduce retinal cell loss and slow disease progression. Three PRP injections were administered to the better-seeing eye at 4-week intervals, while the fellow eye served as an untreated control. Participants were followed from baseline to 10 weeks (two weeks after the third injection). The aim is to compare changes in RPE atrophy area, photoreceptor loss, and visual function between treated and untreated eyes.
Trial Details
NCT Number NCT07428798
Lead Sponsor Marmara University Pendik Training and Research Hospital
Conditions Geographic Atrophy, Dry Age Related Macular Degeneration
Enrollment 14 participants
Start Date 2024-07-01
Primary Completion 2024-10-30 (estimated)
Study Completion 2024-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-24